<SEC-DOCUMENT>0001415889-25-003423.txt : 20250210
<SEC-HEADER>0001415889-25-003423.hdr.sgml : 20250210
<ACCEPTANCE-DATETIME>20250210105539
ACCESSION NUMBER:		0001415889-25-003423
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250210
DATE AS OF CHANGE:		20250210

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Maze Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001842295
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94841
		FILM NUMBER:		25604346

	BUSINESS ADDRESS:	
		STREET 1:		171 OYSTER POINT BOULEVARD, SUITE 300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6508505070

	MAIL ADDRESS:	
		STREET 1:		171 OYSTER POINT BOULEVARD, SUITE 300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Frazier Life Sciences Public Fund, L.P.
		CENTRAL INDEX KEY:			0001863769
		ORGANIZATION NAME:           	
		IRS NUMBER:				862999645
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		650-325-5156

	MAIL ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001863769</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
	      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>02/03/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001842295</issuerCik>        <issuerName>Maze Therapeutics, Inc.</issuerName>        <issuerCusip>578784100</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>171 Oyster Point Blvd., Suite 300</com:street1>
                    <com:city>South San Francisco</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	   				        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
		      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>2376329.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>2376329.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2376329.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.4</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 2,376,617 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding  following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the Securities and Exchange Commission (the "SEC") on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.P. </reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>2376329.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>2376329.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2376329.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.4</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 2,376,617 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding  following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the Securities and Exchange Commission (the "SEC") on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>2376329.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>2376329.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2376329.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.4</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The shares listed in rows 6, 8 and 9 consist of 2,376,617 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the Securities and Exchange Commission (the "SEC") on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences Public Overage Fund, L.P.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>701164.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>701164.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>701164.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.6</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 701,248 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP Overage, L.P.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>701164.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>701164.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.6</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 701,248 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP Overage, L.L.C.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>701164.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>701164.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>701164.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.6</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The shares listed in rows 6, 8 and 9 consist of 701,248 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>41719.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>41719.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>41719.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.1</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 41,719 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.P.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>41719.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>41719.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>41719.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.1</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 41,719 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>41719.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>41719.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>41719.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.1</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The shares listed in rows 6, 8 and 9 consist of 41,719 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>74688.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>74688.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>74688.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.2</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 74,688 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of by Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.
</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>74688.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>74688.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>74688.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.2</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 74,688 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of by Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>74688.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>74688.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>74688.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.2</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The shares listed in rows 6, 8 and 9 consist of 74,688 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of by Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>James N. Topper</reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>3193900.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>3193900.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3193900.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>7.3</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of (i) 2,376,617 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 701,248 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 41,719 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (iv) 74,688 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of by Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.
</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Patrick J. Heron</reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>3193900.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>3193900.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3193900.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>7.3</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of (i) 2,376,617 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 701,248 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 41,719 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (iv) 74,688 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of by Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Albert Cha </reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>3077493.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>3077493.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3077493.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>7.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of (i) 2,376,617 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 701,248 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 41,719 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (iv) 74,688 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of by Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.
</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>James Brush</reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>3077493.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>3077493.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3077493.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>7.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of (i) 2,376,617 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 701,248 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 41,719 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (iv) 74,688 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of by Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Daniel Estes</reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>74688.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>74688.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>74688.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.2</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of 74,688 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of by Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 43,776,978 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering as set forth in the Issuer's Rule 424(b)(4) Prospectus, filed with the SEC on January 31, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>Maze Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>171 Oyster Point Blvd., Suite 300, South San Francisco, CA, 94080.</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>The entities and persons filing this statement (collectively, the "Reporting Persons") are:

Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P. FHMLSP, L.L.C.
Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF")
FHMLSP Overage, L.P.
FHMLSP Overage, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron")
Albert Cha ("Cha")
James Brush ("Brush")
Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")
</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>The address of the principal place of business for each of the Reporting Persons is:

c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite B
Palo Alto, CA 94304
</principalBusinessOfficeOrResidenceAddress>        <citizenship>Entities:		FLSPF 				        -	Delaware, U.S.A.
			FHMLSP, L.P.			        -	Delaware, U.S.A.
			FHMLSP, L.L.C.		        -	Delaware, U.S.A.
			FLSPOF			                -	Delaware, U.S.A.
			FHMLSP Overage, L.P.		-	Delaware, U.S.A.
			FHMLSP Overage, L.L.C.	-	Delaware, U.S.A.
			FLS X				        -	Delaware, U.S.A.
			FHMLS X, L.P.			-	Delaware, U.S.A.
			FHMLS X, L.L.C.		        -	Delaware, U.S.A.
			FLS XI				        -	Delaware, U.S.A.
			FHMLS XI, L.P.		        -	Delaware, U.S.A.
			FHMLS XI, L.L.C.		        -	Delaware, U.S.A.

Individuals:	Topper				        -	United States Citizen
			Heron				        -	United States Citizen
			Cha				                -	United States Citizen
			Brush				        -	United States Citizen
			Estes				        -	United States Citizen
</citizenship>      </item2>

        <item3>
		        <notApplicableFlag>Y</notApplicableFlag>

      </item3>



    <item4>
    <amountBeneficiallyOwned>The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</amountBeneficiallyOwned>    <classPercent>The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>
	          <notApplicableFlag>Y</notApplicableFlag>


    </item5>


        <item6>
	  	  <notApplicableFlag>Y</notApplicableFlag>
		        </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>

      </item10>
    </items>

		<exhibitInfo>Exhibit 99.1 Joint Filing Agreement.</exhibitInfo>

	    <signatureInformation>
      <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C. </title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences Public Overage Fund, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP Overage, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP Overage, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C. </title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C. </title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>James N. Topper</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Patrick J. Heron</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Albert Cha </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>James Brush</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Daniel Estes</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022</title>
        <date>02/10/2025</date>
      </signatureDetails>

    </signatureInformation>



  </formData>


    </edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99-02102025_030236.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex-99-02102025_030236.htm</title></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin:0px" align="center"><br></p>
<p style="margin:0px" align="right"><b>EXHIBIT 99.1</b></p>
<p style="margin:0px" align="right"><br></p>
<p style="margin:0px" align="center"><b>JOINT FILING AGREEMENT</b></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; text-indent:48px" align="justify">Pursuant to Rule&nbsp;13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule&nbsp;13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Maze Therapeutics, Inc.</p>
<p style="margin:0px; text-indent:48px" align="justify">&nbsp;</p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLSP, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; padding-left:336px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP Overage, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLSP Overage, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px; font-family:Times New Roman Bold,Times New Roman" align="justify"><b>FHMLSP OVERAGE, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By FHMLSP Overage, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP OVERAGE, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br><br></p>
<hr style="margin-bottom: 9.6px; padding-top: 9.6px;" noshade size="1"><p style="page-break-before:always;margin-top:0;margin-bottom:-4pt;font-size:4pt"></p><p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES XI, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XI, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS XI, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XI, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XI, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XI, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES X, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS X, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS X, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS X, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS X, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS X, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>*</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">James N. Topper</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>*</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Patrick J. Heron</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>**</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Albert Cha</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>**</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">James Brush</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>***</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Daniel Estes</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 10, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Steve R. Bailey, as Attorney-in-Fact</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify">*This Joint Filing Agreement was executed by Steve&nbsp;R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify">**This Joint Filing Agreement was executed by Steve&nbsp;R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify">***This Joint Filing Agreement was executed by Steve&nbsp;R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
